Many Australians researching growth hormone secretagogues come across Sermorelin through US-based content — podcasts, longevity forums, telehealth clinic websites — and find themselves asking the same questions: Is it available here? How does it compare to CJC-1295 and Ipamorelin? Can an Australian GP prescribe it?
Sermorelin is, in fact, one of the most extensively studied GHRH analogues in clinical and research settings, with a history spanning several decades. This article provides Australian-specific context to help you understand what Sermorelin is, how it differs from other growth hormone secretagogues, and how GP-supervised access works in Australia.
What Is Sermorelin?
Sermorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) — specifically, it replicates the first 29 amino acids of the native 44-amino acid GHRH sequence. Despite being a truncated version of GHRH, Sermorelin retains full receptor-binding activity at the GHRH receptor in the pituitary gland.
In practical terms, this means Sermorelin signals the pituitary gland to release growth hormone (GH) in natural pulses, closely mimicking the body's own GHRH activity. This is a fundamental distinction worth emphasising: Sermorelin does not introduce synthetic growth hormone into the body. It works by stimulating the pituitary's own GH production through a physiological signalling pathway.
Sermorelin was first used clinically in paediatric contexts for the investigation and management of growth hormone deficiency in the 1990s, making it one of the better-studied GHRH analogues available. Its long research history distinguishes it from newer, less-characterised peptides — though all adult use today is off-label via compounding, as discussed below.
How Does Sermorelin Compare to CJC-1295 and Ipamorelin?
Australians exploring GH secretagogues will most commonly encounter CJC-1295 and Ipamorelin — the most commonly prescribed GH secretagogue combination in Australia. Sermorelin operates in the same general space but has meaningful differences worth understanding.
| Peptide | Mechanism | Half-Life | GH Release Pattern |
|---|---|---|---|
| Sermorelin | GHRH receptor agonist | ~20–30 min | Short, pulsatile |
| CJC-1295 | GHRH receptor agonist | Days (with DAC) | Sustained, extended |
| Ipamorelin | GHSR (ghrelin receptor) | ~2 hours | Selective pulses |
Sermorelin is typically administered alone, often at bedtime to align with the body's natural nocturnal GH secretion pattern. This is not to suggest Sermorelin is superior to CJC-1295/Ipamorelin — both approaches have their rationale, and the appropriate choice for any individual is a clinical determination made by a GP.
Why Does Pulsatile GH Release Matter?
Natural GH secretion is pulsatile — the pituitary releases GH in bursts rather than as a continuous stream, with the most significant pulses occurring during deep sleep. GH receptors in the body are designed to respond optimally to this patterned release.
Because of Sermorelin's short half-life, it clears the system quickly after administration, allowing the pituitary's GH response to remain episodic rather than sustained. For protocols where preserving the natural pulsatile character of GH release is a clinical priority, Sermorelin's pharmacokinetic profile may be relevant — though again, suitability is assessed by a GP based on each patient's individual circumstances.
Why Is Sermorelin Less Common in Australia Than in the US?
This is worth addressing directly, because it explains some of the confusion Australians encounter when researching this topic.
In the United States, Sermorelin became the predominant GH secretagogue used in telehealth and hormone optimisation clinics throughout the 2000s and into the 2010s. Much of the English-language online content about Sermorelin reflects this US-centric history.
In Australia, CJC-1295 and Ipamorelin became the more commonly used GH secretagogue combination in peptide-prescribing practices. As a result, Australians encountering Sermorelin from US sources often struggle to find clear, locally relevant information about access.
The practical answer: Sermorelin is accessible in Australia. It is not commercially registered with the TGA — the commercial product (Geref) was discontinued by its manufacturer in 2008, and all adult use since has been off-label via licensed compounding pharmacies. This is the same pathway through which CJC-1295, Ipamorelin, and other peptides are legally accessed in Australia. A valid prescription from an AHPRA-registered GP is required.
For more on how this process works generally, see how to get peptides prescribed in Australia and GP-prescribed vs grey market peptides.
Who Might a GP Consider for Sermorelin?
Suitability for Sermorelin is assessed by a GP on an individual basis. The following is a general profile of the type of adult who may seek this conversation — it is not a prescribing guide or diagnostic tool.
Patients who commonly enquire about Sermorelin tend to be adults broadly in the 35–60 age range who have noticed changes they associate with age-related shifts in GH axis activity: reduced sleep quality, slower recovery, changes in body composition, or reduced energy levels. Many have been researching GH secretagogues independently and are seeking a legal, GP-supervised pathway rather than an unregulated source. Others may have encountered Sermorelin through US content and want to understand the Australian equivalent.
A GP assessment for Sermorelin may include IGF-1 levels and other relevant baseline bloodwork. Sermorelin is generally not considered appropriate for individuals with active or suspected malignancy (given the role of GH signalling in cell growth), those who are pregnant or breastfeeding, or individuals with certain endocrine conditions. As with all peptide therapy, suitability is not self-determined — it requires clinical review.
For context on how safety is addressed in Australian GP practice, see our overview of are peptides safe?
How to Access Sermorelin via Telehealth in Australia
The process through HPH is fully online and individualised:
Complete the Online Health Assessment
Fill out your health history at hphuman.com.au. This gives your GP the clinical context needed for a thorough individual assessment.
GP Reviews and Consults Online
An HPH GP reviews your assessment and consults with you via telehealth. All consultations are with AHPRA-registered doctors experienced in peptide therapy.
Prescription Issued (if appropriate)
If assessed as clinically appropriate, a prescription for compounded Sermorelin is issued and sent directly to a licensed Australian compounding pharmacy.
Dispensed and Delivered
Compounded Sermorelin is prepared by a licensed pharmacy under pharmaceutical quality controls and delivered nationally. Administration is typically by subcutaneous self-injection using a fine needle — your GP will guide you through the technique.
Ongoing Follow-Up with Your GP
Ongoing monitoring and follow-up is provided by your HPH GP. No specific doses or timelines are outlined here — these are clinical decisions made individually. There are no standardised protocols appropriate for all patients.
Frequently Asked Questions
Is Sermorelin available in Australia?
Yes. Sermorelin is not commercially registered with the TGA, but it is legally accessible via licensed Australian compounding pharmacies with a valid prescription from an AHPRA-registered GP. This is the same compounding pathway used for other peptides in Australia.
How does Sermorelin compare to CJC-1295/Ipamorelin?
Both Sermorelin and CJC-1295 work via the GHRH receptor, but they differ in half-life and the pattern of GH stimulation they produce. Ipamorelin works via a separate receptor pathway and is commonly combined with CJC-1295. CJC-1295/Ipamorelin is the more commonly used combination in Australian peptide clinics. Sermorelin offers a shorter-acting, more pulsatile alternative. Your GP will determine which approach — if any — is appropriate based on your individual assessment.
Do I need blood tests before starting?
This is determined by your GP. Assessment for a GH secretagogue protocol typically includes IGF-1 and other relevant bloodwork. No prescription is issued without a clinical assessment — this is a non-negotiable part of responsible prescribing.
Can I access Sermorelin without seeing a doctor?
No. Sermorelin requires a valid prescription from an AHPRA-registered GP. Any Sermorelin product obtained without a prescription is unregulated, outside the legal framework, and potentially unsafe. Quality, purity, and dosage accuracy cannot be assumed from unregulated sources.
Is Sermorelin the same as growth hormone (HGH)?
No — they are fundamentally different. Sermorelin stimulates the pituitary gland to produce and release the body's own growth hormone. It does not introduce synthetic GH into the body. Synthetic human growth hormone (HGH) is classified as a Schedule 8 controlled substance in Australia and is subject to considerably stricter prescribing requirements. Sermorelin and HGH are distinct substances used through distinct clinical pathways.
This article is for informational purposes only and does not constitute medical advice. Peptide therapy must be prescribed by a registered Australian GP following a clinical assessment. Results may vary. Sermorelin is not commercially registered with the TGA and is only accessible through licensed Australian compounding pharmacies with a valid prescription.